ArticleOpen medicine (Warsaw, Poland)2026
Designing a multi-epitope vaccine against yellow fever virus using immunoinformatics approaches.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Yellow fever virus (YFV) is a mosquito-borne pathogen causing severe hemorrhagic fever in tropical and subtropical regions. This study aimed to design and evaluated a multi-epitope subunit vaccine against yellow fever virus using immunoinformatics and computational approaches. Methods: The yellow fever virus envelope glycoprotein was selected as the target antigen. Antigenic, non-allergenic, and non-toxic B-cell, MHC-I, and MHC-II epitopes were predicted and assembled into a vaccine construct using linkers and β-defensin-3 as an adjuvant. Structural modeling and validation were performed using AlphaFold3 and quality assessment tools. Molecular docking with TLR2 and TLR8 was conducted using ClusPro, followed by molecular dynamics simulations to assess structural stability. Disulfide engineering was applied to enhance rigidity, immune simulation was performed to predict host immune responses, and Results: Six conserved epitopes with strong antigenic potential were identified. The vaccine construct showed favorable docking interactions with TLR2 and TLR8, yielding ClusPro weighted interaction scores of -1105.52 and -1152.9, respectively. Molecular dynamics simulations revealed structural stability, supported by stable RMSD and compact radius of gyration profiles. Immune simulation indicated robust humoral and cellular immune responses. Conclusions: The designed multi-epitope vaccine showed promising immunogenic and structural properties, supporting its potential as a potential vaccine candidate against yellow fever virus. However, experimental validation through
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.